Khokon Miah Akanda: 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke
Khokon Miah Akanda, Senior Brand Executive at Apex Pharma Limited, shared on LinkedIn:
“Major Updates in Stroke Care: 2026 AHA/ASA Guidelines Released Today
The American Heart Association and American Stroke Association have released the 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke. These updates represent significant shifts in prehospital triage, thrombolytic choices, and post-procedural management.
Key Takeaways for Clinicians and Industry Leaders:
• Tenecteplase is Mainstream: The guidelines now endorse Tenecteplase (0.25 mg/kg) as a reasonable alternative to Alteplase for eligible patients within the 4.5-hour window.
• Expanded EVT Eligibility: Endovascular Thrombectomy (EVT) is now strongly recommended for select patients with large ischemic core strokes and basilar artery occlusions.
• Prehospital Triage: New emphasis on direct transport to EVT capable centers for suspected Large Vessel Occlusion (LVO), bypassing smaller centers when appropriate logistics exist.
• Pediatric Care: For the first time, guidelines include specific recommendations for endovascular treatment in children.
Management Shifts
Mild Stroke: Routine IV thrombolysis is not recommended for non-disabling deficits; Dual Antiplatelet Therapy (DAPT) is preferred.
Blood Pressure: Intensive lowering (<140 mm Hg) immediately post-reperfusion is not recommended and may be harmful.
Glycemic Control: Intensive glucose control between (80-130 mg/dL) is advised against due to hypoglycemia risk.
These guidelines push for faster, more precise interventions and open new doors for therapeutic options.”
Stay updated with Hemostasis Today.
-
May 6, 2026, 11:30Paula Caporal: Consensus on the Diagnosis and Management of Pediatric Stroke in Argentina
-
May 6, 2026, 11:14Li Khim Kwah: Proud for the Development of The New Singapore Stroke Rehabilitation Guideline
-
May 6, 2026, 10:55Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
-
May 6, 2026, 10:40Ifeanyichukwu Ifechidere: Why INR Can Be Dangerously Misleading
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Connecting with so Many Families and Advocates at HFA 2026
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?
-
May 6, 2026, 02:23Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
-
May 6, 2026, 02:12Caitlin Raymond: How STOP-BABESIOSIS Just Rewrote 40 Years of Practice